about
Interleukin-17 production and T helper 17 cells in peripheral blood mononuclear cells in response to ocular lysate in patients with birdshot chorioretinopathyA bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.Development of an IFNγ ELISPOT for the analysis of the human T cell response against mumps virus.The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs.Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopesSepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.Mumps infection but not childhood vaccination induces persistent polyfunctional CD8+ T-cell memory.Application of cultured human regulatory T cells requires preclinical in vivo evaluationThe Human CD4 T Cell Response against Mumps Virus Targets a Broadly Recognized Nucleoprotein EpitopeHuman regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient miceForced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cellsLenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 TrialEfficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients
P50
Q24625664-2EEAE692-B324-430B-BBDA-46E79AD1CFBAQ39980314-06155D29-F738-4584-8674-A352DA746602Q40001063-2F7217F8-4C81-46A8-9374-86C70AE5FB6CQ41179482-E3B9A3E0-21AE-48B5-B880-75C6F72494C5Q41703140-95597FD0-FA7E-44B2-BFC3-1284C08AB3AAQ42391580-AC781B1A-586A-4548-AF5D-6A2A9816FCDBQ46375251-CC84590D-F5D5-496F-9E5D-22C8DF1FDE6FQ50021108-BB445581-C2EC-43D5-949A-4E114D36C453Q56898239-C50A5123-F563-4845-A741-57CAA47FDD31Q64063752-9CFE8C92-0BD9-4945-B929-65686EAB50B7Q79136710-E7E72989-8EC5-43BD-998D-855E0423586EQ81083994-0B4EB9C9-4B09-46E1-8FB3-BC6CC8527817Q84401841-8880F5BD-98F2-4CFB-847D-802F4C3A351DQ88758936-1C3DF559-0D01-4DDE-99BC-2DDD0B0B00D7
P50
description
researcher ORCID ID = 0000-0002-4930-6268
@en
wetenschapper
@nl
name
Maarten Emmelot
@ast
Maarten Emmelot
@en
Maarten Emmelot
@es
Maarten Emmelot
@nl
type
label
Maarten Emmelot
@ast
Maarten Emmelot
@en
Maarten Emmelot
@es
Maarten Emmelot
@nl
prefLabel
Maarten Emmelot
@ast
Maarten Emmelot
@en
Maarten Emmelot
@es
Maarten Emmelot
@nl
P31
P496
0000-0002-4930-6268